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Abstract
Attempts to enhance a patient’s immune response and ameliorate the poor prognosis of ovarian cancer (OVCA) have
largely been unsuccessful owing to the suppressive tumor microenvironment. Leukocyte immunoglobulin-like tran-
script 3 (ILT3) inhibitory receptors have been implicated in immunosuppression in several malignancies. The ex-
pression and role of ILT3 in the progression of ovarian tumors are unknown. This study examined the expression
and association of ILT3 in ovarian tumors in laying hens, a spontaneous preclinical model of human OVCA. White
Leghorn laying hens were selected by transvaginal ultrasound scanning. Serum and normal ovaries or ovarian tumors
were collected. The presence of tumors and the expression of ILT3 were examined by routine histology, immuno-
histochemistry, Western blot analysis, and reverse transcription–polymerase chain reaction. In addition to stromal
immune cell-like cells, the epithelium of the ovarian tumors also expressed ILT3 with significantly high intensity than
normal ovaries. Among different subtypes of ovarian carcinomas, serous OVCA showed the highest ILT3 staining
intensity, whereas endometrioid OVCA had the lowest intensity. Similar to humans, an immunoreactive protein
band of approximately 55 kDa for ILT3 was detected in the ovarian tumors in hens. The patterns of ILT3 protein
and messenger RNA expression by ovarian tumors in different subtypes and stages were similar to those of immuno-
histochemical staining. The results of this study suggest that laying hens may be useful to generate information on
ILT3-associated immunosuppression in OVCA. This animal model also offers the opportunity to develop and test
anti-ILT3 immunotherapy to enhance antitumor immunity against OVCA in humans.
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Introduction
Despite the remarkable improvements in cytoreductive surgeries and
chemotherapeutics, ovarian cancer (OVCA) remains one of the most
lethal gynecologic malignancies of women with a high death rate [1].
Owing to the lack of an effective early detection test, OVCA in most
cases is detected at late stages, and its high recurrence rate (80%-90%)
contributes to poor prognosis [2,3]. There is an emerging recognition
that tumor growth, in general, elicits specific immune responses me-
diated by cell-mediated immunity [4]. As a result, immunotherapies
against several cancers are being developed [4–6]. Although recent
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advances in immunotherapy have been shown to improve the over-
all survival ability of patients with hematologic tumors and mela-
noma [7], most immunotherapeutic trials have failed to demonstrate
success in clinical responses [6,8]. Thus, development of new strat-
egies to promote immune responses against malignancies is critical in
overcoming the limited efficacy of conventional therapies. Despite
the presentation of antigens by ovarian malignant cells, which should
induce immune-mediated rejection, spontaneous rejection of an estab-
lished tumor is rare [9]. This lack of immune response is not only
because of the ignorance of the immune system but also because of
the tumor-induced immune suppression that protects the tumor from
eradication [9]. Therefore, a better understanding of the mechanisms
of tumor-induced immunosuppression will enhance our ability to
prevent ovarian tumor progression and to design antitumor interven-
tional strategies.
Numerous studies on cancers of several organs have reported several
mechanisms of tumor-induced immune suppression including induc-
tion of regulatory T cells [10], expression of immunosuppressive fac-
tors (transforming growth factor β, interleukin 10, and chemokine
ligand 22) [10–12], down-regulation of intracellular adhesion mole-
cules [13], and induction of peripheral tolerance [4,14,15]. In contrast,
studies on the mechanism of immune suppression in ovarian malig-
nancy are very limited. OVCA differs from other malignancies in its
specific dissemination pattern [9]. The tumor typically spreads in a dif-
fuse intra-abdominal fashion rather than through systemic circulation.
Thus, antitumor immune response at the tumor environment plays a
critical role to ovarian tumor metastasis. Immunosuppressive regulatory
T cells [10], transforming growth factor β [11,12], tolerance-inducing
plasmacytoid dendritic cells [16], B7-H4+ macrophages [17], and
interleukin 10 [18] have been reported to be present in the tumor
microenvironment. However, how these immunosuppressive factors
and agents are recruited into the tumor environment is not known.
Emerging studies suggest that induction of inhibitory receptor immuno-
globulin (Ig)-like transcript 3 (ILT3) expression is one of the mecha-
nisms contributing to the tumor-induced immune suppression in
several malignancies [19].
ILT3 is a member of leukocyte Ig-like receptors family with inhib-
itory functions and exists in both membrane and soluble forms [20].
Both forms of ILT3s have been suggested to inhibit T-cell prolifera-
tion, CD4+ T-cell anergy, suppressing the differentiation of interferon
γ–producing CD8+ cytotoxic lymphocytes. In addition, membrane and
soluble ILT3 were also reported to stimulate the differentiation of regu-
latory T cells in various cancer patients [4,5,10]. All these findings
suggest that ILT3 may be involved in the immunosuppression against
tumor antigens and prevention or blocking of ILT3 expression may
enhance a patient’s immune responses to malignancies. The expression
of ILT3 in OVCA patients has not yet been reported. Difficulties in
identifying and access to patients at the early stage of OVCA hinder
the ability to study the involvement of ILT3 in OVCA progression
and develop interventional strategies for its prevention. Rodents do
not develop OVCA spontaneously, and the histopathologies of induced
OVCA in rodents do not resemble the spontaneous OVCA in humans
[21]. Recently, we have shown that laying hens are the only widely
available animals that develop OVCA spontaneously with a high inci-
dence rate and histopathologies remarkably similar to human OVCA
[22]. The expression of leukocyte Ig-like receptors has been reported
in chicken, which are shown to be orthologus to those of mammals
including humans [23,24]. Thus, the goal of this study was to examine
whether ILT3 is expressed in ovarian tumors in the laying hen model of
spontaneous OVCA and, if so, whether ILT3 expression is associated
with the progression of ovarian tumors in hens.
Materials and Methods
Animals
Commercial strains of approximately 3-year-old white Leghorn
laying hens (Gallus domesticus) were selected from a flock of layers
maintained under standard poultry husbandry practices. The incidence
of OVCA in hens of this age group is approximately 15% to 20%
and is associated with low or complete cessation of egg laying [25].
Hens (n = 148) were selected on the basis of their egg-laying rates
(normal, low, or ceased egg laying) and transvaginal ultrasound scan-
ning as reported previously [25]. All experimental procedures were per-
formed according to the institutional animal care and use committee
approved protocol.
Tissue Collection and Processing
Serum samples. Blood was obtained from brachial veins of all hens
before euthanasia, centrifuged (1000g for 20 minutes), and serum
samples were stored at −80°C until further use.
Gross ovarian morphology and histopathology. Ovarian pathology
and tumor staging were performed by gross and histologic examination
as reported previously [22]. Each normal ovary or ovary with tumor was
divided into four portions for protein extraction, total RNA collection,
paraffin and frozen embedding for routine histology, and immuno-
histochemical studies as reported previously [26]. Ovarian surface epi-
thelial (OSE) cells from normal or ovaries with tumor were collected
similarly as reported earlier [27]. All collected samples were grouped
into three groups including normal-, early-, and late-stage OVCA based
on the diagnosis of the histopathologic ovarian tissue examination as
reported previously [22].
Preparation of Ovarian Specimen for Biochemical Analysis
Snap-frozen normal ovaries and ovaries with tumor as well as OSE
from normal ovaries and ovaries with tumor were homogenized with a
Polytron homogenizer (Brinkman Instruments, Westbury, NY) as re-
ported previously [28] and centrifuged, the supernatant was collected,
and the protein content of the extract was measured and stored at
−80°C until further use.
Histopathologic Examination and Immunohistochemistry
Paraffin or frozen sections from each ovary with tumor or ovaries that
appeared normal without any grossly detectable tumor were stained with
hematoxylin and eosin and observed under a light microscope. Presence
or absence of tumors in the section and their histologic types were de-
termined as reported earlier [22]. Immunohistochemical detection of
ILT3 expression was performed using goat anti-ILT3 (R&D Systems,
Inc, Minneapolis, MN) as primary antibodies (n = 15 hens each, for
normal, early, and late stages as reported previously) [26]. The number
of hens for each group was determined based on statistical power analy-
sis to achieve significant differences in the intensities of ILT3 immuno-
staining among the hens of normal or OVCA groups. These hens were
selected from each group randomly. Briefly, sections were deparaffinized,
and antigens on the sections were unmasked by heating the sections with
an antigen-unmasking solution (Vector Laboratories, Burlingame, CA)
for 20 minutes in a microwave oven. Endogenous peroxidase in the
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sections was inactivated, and nonspecific staining was blocked by incu-
bating with 0.3% hydrogen peroxide in methanol for 30 minutes
followed by 1% (vol/vol) normal horse serum for 15 minutes, respec-
tively. Sections were then incubated overnight with primary antibodies
(1:100 dilution) followed by 1 hour of incubation with anti-goat IgG-
HRP secondary antibodies (R&D Systems). Immunoprecipitates on
the sections were visualized by incubation with a mixture of diamino-
benzidine and hydrogen peroxide in diaminobenzidine buffer (Vector
Laboratories). Sections were then counterstained with hematoxylin,
dehydrated, and covered. Control staining was carried out simultaneously
in which the first antibodies were omitted and normal goat serum was
used. No staining was found in these control slides.
Sections were then examined under a light microscope attached to
digital imaging software (MicroSuite version 5; Olympus Corporation,
Tokyo, Japan). Three sections per ovary and five regions of interest
(20,000 μm2/region at ×40 objective and ×10 ocular magnification)
per section were randomly selected. Using the software, the intensity
of the ILT3 immunostaining in each region was measured and re-
corded as pixel values in 20,000 μm2 of the section. The mean of pixel
values of these five regions in a section was considered as the intensity
of each section, and the mean of intensities of three sections was con-
sidered as the mean of ILT3 staining intensity in normal or tumor-
bearing ovaries.
One-dimensional Western Blot
The expression of ILT3 proteins by normal ovaries or ovarian tumors
as well as OSE from normal ovaries or ovaries with tumor was deter-
mined byWestern blot analysis using primary and secondary antibodies
mentioned above. On the basis of immunohistochemical staining re-
sults, representative samples of ovarian as well as OSE homogenates
from normal or ovarian tumors at early and late stages were used in im-
munoblot analysis. Immunoreactions on the membrane were visualized
as a chemiluminescence product (Super Dura West substrate; Pierce/
Thermo Fisher, Rockford, IL), and the image was captured using a
Chemidoc XRS (Bio-Rad, Hercules, CA). Digital images obtained with
Chemidoc XRS were analyzed by Quantity One software (Bio-Rad)
according to the manufacturer’s recommendation, and the intensities
of immunoreactive bands were expressed as density per intensity in
squared millimeter and the mean of intensities for each normal or
pathologic group as well as for the stages of OVCA were calculated.
No immune reaction was observed in controls where protein sam-
ples were omitted. Serum samples for Western blot analysis were se-
lected similar to ovarian samples and tested to confirm the presence of
soluble ILT3.
Reverse Transcription–Polymerase Chain Reaction
ILT3 messenger RNA (mRNA) expression in ovarian tissues or
epithelial cells from normal hens or hens with OVCA was assessed
by semiquantitative reverse transcription–polymerase chain reaction
(RT-PCR) as reported previously [29]. Representative samples of nor-
mal ovaries or ovaries with tumor as well as OSE from hens were
selected for RT-PCR analyses based on their immunoreactivities in
immunohistochemistry and immunoblot analysis were used. Hen-
specific ILT3 primers were designed by Oligoperfect Designer software
(Invitrogen, Carlsbad, CA) using the ILT3 sequence from the National
Center for Biotechnology Information (GenBank: NM_001146134.1).
The forward primer was 5-TGG CTG TAC CAG GAA AGA GG
and the reverse primer was 5-CTC TGA TGC CCC TAC TGA CC.
β-Actin was used as the endogenous control with a forward primer of
TGCGTGACATCAAGGAGAAG and a reverse primer of ATGC-
CAGGGTACATTGTGGT. The expected base pair size for the ILT3
amplicon was 150 bp and that for β-actin was 300 bp. PCR amplicons
were visualized in a 3% agarose gel (Pierce) in TAE buffer and stained
with ethidium bromide, and images were captured using a ChemiDoc
XRS system (Bio-Rad). PCR products were sequenced, and the sequence
was the same as the sequence of primers from the National Center for
Biotechnology Information GenBank (NM_001146134.1).
Statistical Analysis
The differences in the pixel intensities of ILT3 immunostaining
among different histologic subtypes and stages (early vs late) were as-
sessed by two-way analysis of variance. This was followed by pairwise
comparison between the histologic subtypes (normal, endometrioid,
mucinous, and serous) within each stage and comparison of the
stages within histologic subtypes by two-sample t tests and alternative
Mann-Whitney tests. All reported P values are 2-sided, and P < .05
was considered significant. Statistical analyses were performed with
SPSS (PASW) version 18 software (IBM, Inc, Armonk, NY) and
R statistical software.
Results
Morphologic and Histologic Features of Hen Ovaries and
Ovarian Tumors
Gross morphology. A fully functional ovary in a healthy laying hen
contained five to six developing large preovulatory follicles (Figure 1A),
whereas the ovaries of low-laying healthy hens contained less than
three preovulatory follicles. In normal hens that had stopped egg lay-
ing, ovaries and oviducts were regressed without any detectable ab-
normality. Solid tissue masses either limited to a small part or to the
whole ovary and with or without ascites were observed in 14 hens and
Figure 1. Gross morphology of normal ovaries and ovaries with
tumor in laying hens. (A) Normal ovary: A normal laying hen ovary
contained a hierarchy of multiple large preovulatory follicles (F1-F3)
with an active oviduct. (B) OVCA at early stage in a laying hen. The
tumor mass was limited to the ovary (shown in a dotted circle).
(C and D) OVCAs at late stages in laying hens. Tumors were metas-
tasized to distant organs including intestine (C) and liver (D, arrows
indicate the examples of tumor seeding) with accompanied profuse
ascites (*).
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classified as hens with early-stage OVCA (Figure 1B). In 17 hens, the
tumor had metastasized to abdominal organs with moderate to profuse
ascites and classified as hens with late-stage OVCA (Figure 1, C andD).
Histopathology. A total of 105 hens were found to have normal
ovaries in which embedded primordial and primary follicles were ob-
served in the ovarian stromal tissue (Figure 2A). Ovarian tumors were
confirmed by routine histology in 31 hens that had solid masses limited
to the ovaries (n = 14, early stage) or metastasized to other organs
(n = 17, late stage). In addition, microscopic OVCAs were detected
in 12 hens without any grossly detectable solid mass in the ovary and
grouped in early-stage OVCA. Thus, a total of 26 (14 + 12) hens
had early and 17 had late-stage OVCA. Tumors were typed (Figure 2,
B-D) as serous (n = 18), endometrioid (n = 13), mucinous (n = 10),
as well as mixed (n = 2, seromucinous and endoserous) as reported
previously [22].
Tissue Expression of ILT3
Immunohistochemical detection of ovarian ILT3 expression.
T-lymphocyte-like rounded cells and macrophage-like irregular-
shaped cells in the stroma of normal ovaries or ovaries with tumor were
found positive for ILT3. Some surface epithelial cells (not all) above
the developing cortical follicles in normal ovaries and the epithelium
of the ovarian tumors were also stained positive for ILT3 expression
(Figure 3, A-D). The expression of ILT3 by the epithelial cells of
the tumor in hens with OVCA varied with respect to the histologic
subtypes of tumors and their stages. As compared with normal hens
(mean ± SD = 23029.23 ± 2725.01), the intensities of ILT3 expression
were significantly higher (P < .001) in hens with early-stage OVCA
irrespective of their histologic subtypes (Figure 4). Similar patterns were
also observed for hens with late-stage OVCA.
Among different histologic subtypes at early-stage OVCA, the inten-
sities of ILT3 staining were lowest in hens with ovarian endometrioid
tumors (mean ± SD = 36,807.56 ± 2843.56) followed by mucinous
(40,207.86 ± 2858.27) and highest in serous OVCA (40,924.40 ±
1400.26) in a 20,000-μm2 area of tissue (Figure 4). The differences in
ILT3 staining intensities were significantly higher in hens with serous
OVCA than hens with endometrioid OVCA irrespective of their stages
(P < .028 and .025 for early and late stages of OVCA, respectively).
However, significant differences in ILT3 staining intensities were not
observed between the hens with ovarian endometrioid and mucinous
OVCA as well as mucinous and serous OVCA at early and late stages.
In hens with serous OVCA, the intensities of ILT3 staining were sig-
nificantly high in late stages than in early stage (P < .05). However, a
significant difference in ILT3 staining intensities between the early and
late stages of hens with ovarian endometrioid or mucinous OVCA was
not observed.
Immunoblot analysis for ILT3 protein in ovarian tissues and serum
samples. Immunohistochemical observation of ILT3 expression was
confirmed by immunoblot analysis using homogenates of normal
ovaries and ovaries with tumors as well as OSE from normal ovaries
and ovarian tumors. As expected, immunoreactive ILT3 protein with
a band size of approximately 55 kDa was detected in the homogenates
of OSE and ovarian tissues from normal hens and hens with OVCA at
early stage (Figure 5A). Similar patterns were also observed for serum
Figure 2. Histologic presentation of different types ofmalignant ovar-
ian tumors in laying hens detected in the present study. Formalin-
fixedparaffin-embeddedovarian tissueswere stained for hematoxylin
and eosin. (A) A section of a normal ovary showing a follicle em-
bedded in the ovarian stroma. (B) A section of an ovarian serous
carcinoma-containing tumor cells with large pleomorphic nucleus
and mitotic nuclear bodies. (C) A section of an ovarian endometrioid
carcinoma showing confluent back-to-back tumor glands containing
a single layer of epithelium with sharp luminal margin. (D) A section
of an ovarian mucinous carcinoma. The tumor contained a single
layer of columnar epithelium with intercalated ciliated goblet cells.
Mucin-like secretion is seen in the lumen of the tumor gland (*). Origi-
nal magnifications: ×40. F indicates follicle; S, stroma; Tu, tumor.
Figure 3. Expression of ILT3 by normal ovaries or ovaries with tumor
in laying hens. (A) A section of normal ovary showing ILT3+ OSE
cells (examples are shown by arrows) near a developing follicle.
An immune cell-like ILT3+ cell is seen beneath the ovarian surface
(arrowhead). (B-D) Expression of ILT3 by the epithelium of the ovar-
ian serous (B), endometrioid (C), and mucinous (D) carcinomas at
late stages in laying hens. Intense staining for ILT3 by epithelial cells
of the tumors was observed in all tumor types. F indicates follicle;
G, granulosa layer; T, theca layer; TS, tumor stroma.
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samples (data not shown). Compared with the normal OSE or OSE
from ovarian tumors at early stage, ILT3 protein expression was stron-
ger in the OSE from hens at late-stage OVCA (Figure 5A). Conversely,
the expression of immunoreactive ILT3 proteins was weaker in the
homogenates of ovarian endometrioid tumors, moderate in mucinous,
and stronger in ovarian serous tumors at the early stage (Figure 5A).
Similar patterns were also observed for ovarian tumors at late stage (data
not shown). These results confirm the immunohistochemical observa-
tion that epithelial cells of ovarian tumors in hens express ILT3.
Expression of ILT3 mRNA. Observed variations in ILT3 protein
expression among different histologic subtypes of OVCA and their
stages were confirmed by ILT3 mRNA expression. Hens with early
serous and mucinous ovarian tumors showed strong amplification sig-
nal for ILT3, whereas its amplification was low for endometrioid ovar-
ian tumors. However, no differences were observed for ILT3 mRNA
expression by different histologic subtypes of late-stage OVCA
(Figure 5B). Similar patterns were also observed for the epithelial cells
of ovarian tumors. Thus, the results of gene expression study confirm
the immunohistochemical and immunoblot analysis observations that
the epithelium of ovarian tumors expresses ILT3 proteins.
Discussion
This is the first report on the expression of ILT3 by the epithelium
of ovarian tumors in laying hens, an animal model of spontaneous
OVCA. This study showed that the expression of ILT3 increases signifi-
cantly in association with ovarian tumor development and progression.
These results suggest that laying hens can be used to generate information
on the mechanism of spontaneous ovarian tumor–associated immuno-
suppression and may lead to the development of antitumor immuno-
therapies and the testing of their efficacies.
Recent progresses in the understanding of tumor-immune interac-
tions have led to the successful development of a number of immunother-
apeutic approaches. However, tumor escape from immune recognition
is a significant barrier to the success of these immunotherapies. Although
the process of escaping immune surveillance by tumors or suppression
of antitumor immune response is not well understood, tumor cells,
immune cells, and other stromal cells in the tumor surroundings have
been reported to interact and create an immunosuppressive micro-
environment through a variety of immunosuppressive factors [30]. En-
hanced expression of ILT3 by few members of the immune system has
been suggested as one of such immunosuppressive factors in the tumor
microenvironment [31]. In the present study, in addition to immune
cell-like cells, the epithelium of the ovarian tumors in laying hens also
Figure 5. Examples of immunoreactive ILT3 protein (A) or mRNA (B)
expression in the homogenates of OSE and ovaries from normal
hens or hens with OVCA by one-dimensional Western blot (WB)
analysis and semiquantitative PCR, respectively. One-dimensional
WB (A): Immunoreactive ILT3 protein of approximately 55-kDa mo-
lecular weight was detected in the 1) OSE extract from normal or
ovarian tumors and 2) homogenates from different histologic sub-
types of ovarian tumors at early stage of OVCA. Compared with
the normal OSE or OSE from ovarian tumors at early stage, ILT3
protein expression was stronger in the OSE from hens at late-stage
OVCA. Serous ovarian tumors at the early stage showed strong
ILT3 staining followed by mucinous and endometrioid tumors. No
ILT3 expression was detected in negative control in which protein
sample was omitted. RT-PCR (B): mRNA expression by the OSE
extract from normal or ovarian tumor and from different histologic
subtypes of ovarian tumors at early and late stages of OVCA. Com-
pared to the normal OSE, or OSE from ovarian tumor at early stage,
a strong expression of ILT3 mRNA was observed in the OSE from
hens with late-stage OVCA. Similarly, strong expression patterns
were also observed for the homogenates of ovarian tumors at
late stages than early stages irrespective of tumor subtypes. As
observed in immunohistochemistry and immunoblot analysis, endo-
metrioid tumors at early stage were weaker in ILT3 mRNA expres-
sion than their counterpart serous and mucinous tumors. No ILT3
mRNA expression was detected in the negative control in which
mRNA sample was omitted.
Figure 4. Changes in the ovarian ILT3 expression are associated
with ovarian tumor development and progression. The intensity
of ILT3 staining is expressed as pixel values (mean ± SD) in a
20,000-μm2 area of the ovarian stroma in normal ovaries or ovaries
with tumor. Compared with normal hens, the intensities of the
ILT3 staining were significantly greater in hens with early-stage
OVCA (P < .001) and increased further in hens with late-stage
OVCA irrespective of their tumor types. The intensity of ILT3 stain-
ing was significantly lower (P < .03) in hens with endometrioid
OVCA than hens with serous OVCA. Significant differences were
not observed in the intensity of ILT3 staining between the hens
with serous and mucinous OVCA irrespective of their stages. Bars
with different letters within the same group indicate significant
differences in ILT3 staining intensity.
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expressed ILT3. Under normal physiological condition, ILT3 has been
reported to be expressed selectively by professional antigen-presenting
cells including monocytes, macrophages, and dendritic cells [32]. The
expression of ILT3 on exposure to alloantigen-specific suppressor T cells
or cytokines by nonprofessional antigen-presenting cells, like endo-
thelial cells as well as tumor cells from chronic lymphocytic leukemia,
was also reported previously [33,34]. Thus, the present results suggest
that ovarian tumors also express immunosuppressive ILT3 as reported
for few other cancers.
In the present study, compared with normal hens, the intensity of the
ILT3 expression was significantly high in hens with early-stage OVCA
and increased further as the disease progressed to late stages, suggesting
that changes in ILT3 expression may be associated with ovarian tumor
development and progression. The presence of active antitumor im-
mune responses against ovarian tumors at the early stage has been
reported earlier [9]. However, despite the presence of an antitumor im-
mune response, OVCAs in most cases, progress to late stages. Although
the precise mechanisms of such immune escaping are not known,
our results suggest that the enhanced expression of immune inhibitory
receptor ILT3 by the ovarian tumors may contribute to the progression
of OVCA.
The results of the present study suggest that the expression pattern
of ILT3 varies with the different histologic subtypes of ovarian tumors.
Significantly high ILT3 staining intensity was observed in serous com-
pared with endometrioid ovarian tumors at early as well as late stages
of OVCA. The specific reasons for higher ILT3 expression by serous
OVCA are not known. It is possible that higher ILT3 expression will
contribute to the faster progression of OVCA by imparting higher
immune tolerance to tumors. Serous malignant ovarian tumors are
considered aggressive tumors, and increased ILT3 expression may con-
tribute to their faster progression. Similar observations in cancers of
other organs were also reported previously [31,34]. Thus, it is possible
that ILT3 will contribute to ovarian tumor progression by suppressing
antitumor immunity.
In the present study, a portion of the epithelial cells of the normal
ovarian surface epithelium above the cortical developing follicles (not
all epithelial cells) were positive for ILT3 expression albeit with lower
intensity than the epithelium of ovarian tumors. Although the precise
reason(s) for such expression is not known, it is possible that ILT3
expressed by surface epithelial cells near cortical follicles will protect
them from immune cells by suppression of local antifollicular auto-
immune response. Various structures in the developing follicles in-
cluding the perivitelline membrane, granulosa and theca layers, as
well as the degenerated cellular components of postovulatory follicles
may appear as “foreign” to the circulating immune cells because these
structures were not present during the evolution and maturation of the
immune system.
Our understanding regarding the biology and the role of ILT3 in
the context of OVCA is very limited, in part, because of the lack of
an animal model that develops spontaneous OVCA. Because of the
difficulty of detecting OVCA at an early stage, access to patient speci-
mens to study and develop an effective antitumor immunotherapy is
difficult and time consuming. Similarities between the spontaneous
OVCA in humans and hens in histologic subtypes, risk factors (e.g.,
incessant ovulation), and expression of several molecular makers of
OVCA represent a high probability that results obtained from this
study may be translated to clinics. Furthermore, one of the most im-
portant advantages of this animal model relative to the possibilities
of translating current findings to OVCA in humans is the ability to
monitor hens by contrast enhanced ultrasound imaging using equip-
ment and mechanical setting similar to those used in clinics [25,26].
Thus, there will be less variation in imaging parameters between hens
and humans because of the use of similar equipment. With the ad-
vancement in in vivo imaging technology, ligands that bind to the
epithelial cells of the ovarian tumor are being developed to use as anti-
tumor therapies, and their effectiveness in tumor ablation can be
monitored in this animal model using contrast-enhanced ultrasound
scanning [35]. Because the epithelial cells of the tumor in OVCA hens
express ILT3, laying hens may be used to test the efficacy of anti-ILT3
drug by molecular-targeted ultrasound imaging of ovarian tissues.
Thus, it will bring a significant change in the development of tumor
specific therapeutics specially immunoenhancing drugs and lead to
the development of treatment modalities for OVCA patients. Taken
together, information on ILT3 expression and its association with
OVCA progression will aid in the development of anti-ILT3 immuno-
therapies, which will lay the foundation for clinical studies and may
ultimately lead to the development of effective therapies for the treat-
ment of OVCA.
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